A Study of Rucaparib Verses Physician's Choice of Therapy in Pati

The purpose of this study is to determine how patients with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib verses treatment with physician's choice of abiraterone acetate, enzalutamide, or docetaxel.

July 03, 2017

  • Clinical Trial Information

    Trial Contact: Rompola, Melissa; Ferry, Robert, P.

    Trial Phone: 321.841.7022 ; 321-841-1077

  • Age Group: Adult

    Phase: Drug: Phase III

    Principal Investigator: Julio J. Hajdenberg, MD

    Sub Investigators: Daniel Ari Landau, MD;

    IRB No: 17.007.01

    Secondary Protocol No: CO-338-063

    Applicable Disease Sites: Metastatic Castration Resistant Prostate Cancer